DeepMed Research

Primaquine

Generic Name: Primaquine

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₁N_₃O

CAS Number: 90-34-6

Unique Ingredient Identifier: MVR3634GX1

Background: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)

Indication: For the treatment of malaria.

Associated Conditions: Malaria, Malaria caused by Plasmodium ovale, Malaria caused by plasmodium vivax, Pneumocystis Jirovecii Pneumonia

Clinical Trials

Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand

Completed

Conditions: Malaria, Vivax
G6PD Deficiency

Interventions: Drug: Tafenoquine
Drug: Primaquine

First Posted Date: 2023-03-03

Last Posted Date: 2023-10-26

Lead Sponsor: Dr. Prayuth Sudathip

Target Recruit Count: 187

Registration Number: NCT05753150

Locations: 🇹🇭
Malaria Clinic, Than To, Yala, Thailand
🇹🇭
District Hospital, Than To, Yala, Thailand

Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali

Phase 2

Completed

Conditions: Malaria,Falciparum

Interventions: Drug: Artemether-lumefantrine
Drug: Artesunate-amodiaquine combination
Drug: Amodiaquine
Drug: Primaquine Phosphate

First Posted Date: 2022-09-22

Last Posted Date: 2024-09-30

Lead Sponsor: London School of Hygiene and Tropical Medicine

Target Recruit Count: 100

Registration Number: NCT05550909

Locations: 🇲🇱
Malaria Research and Training Centre, Bamako, Mali

Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru

Recruiting

Conditions: Malaria, Vivax

Interventions: Diagnostic Test: G6PD testing
Other: Training on revised algorithm
Drug: Tafenoquine
Other: Enhancing Pharmacovigilance
Other: Supervision of malaria services in selected facilities.
Drug: Primaquine
Other: Follow Up Visit at Day 3 [+2 days] after treatment start

First Posted Date: 2022-05-04

Last Posted Date: 2023-12-05

Lead Sponsor: Medicines for Malaria Venture

Target Recruit Count: 40

Registration Number: NCT05361486

Locations: 🇵🇪
Nauta Nucleo- Base, Nauta, Loreto, Peru

Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia

Phase 2

Withdrawn

Conditions: Malaria, Vivax
Relapse

Interventions: Drug: Primaquine double dose over 14 days
Drug: Primaquine single dose over 14 days

First Posted Date: 2022-02-09

Last Posted Date: 2023-05-11

Lead Sponsor: University of California, San Francisco

Registration Number: NCT05232227

Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Active, not recruiting

Conditions: Malaria, Vivax
G6PD Deficiency

Interventions: Drug: Primaquine
Drug: Tafenoquine

First Posted Date: 2021-10-27

Last Posted Date: 2023-06-13

Lead Sponsor: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

Target Recruit Count: 16000

Registration Number: NCT05096702

Locations: 🇧🇷
Grande Vitória, Manaus, AM, Brazil
🇧🇷
Efigênio Salles (UBSR), Manaus, AM, Brazil
🇧🇷
Cooperativa I, Manaus, AM, Brazil

and more 38 locations

Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali

Phase 2

Completed

Conditions: Malaria,Falciparum

Interventions: Drug: Sulphadoxine-pyrimethamine with amodiaquine
Drug: Artemether-lumefantrine
Drug: Primaquine Phosphate
Drug: Tafenoquine

First Posted Date: 2021-10-18

Last Posted Date: 2022-01-18

Lead Sponsor: London School of Hygiene and Tropical Medicine

Target Recruit Count: 80

Registration Number: NCT05081089

Locations: 🇲🇱
Malaria Research and Training Centre, Bamako, Mali

Study to Evaluate Primaquine for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children

Phase 2

Completed

Conditions: Malaria, Vivax

Interventions: Drug: Primaquine

First Posted Date: 2021-09-16

Last Posted Date: 2025-02-20

Lead Sponsor: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

Target Recruit Count: 100

Registration Number: NCT05044637

Locations: 🇧🇷
Universidade Federal do Acre, Cruzeiro Do Sul, Acre, Brazil
🇧🇷
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil

Tafenoquine and Primaquine in Colostrum and Breast Milk

Phase 4

Withdrawn

Conditions: Healthy Lactating Women

Interventions: Drug: Primaquine
Drug: Tafenoquine

First Posted Date: 2021-08-02

Last Posted Date: 2024-04-04

Lead Sponsor: University of Oxford

Registration Number: NCT04984759

Locations: 🇹🇭
Shoklo Malaria Research Unit (SMRU), Mae Sot, Tak, Thailand

Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities

Not Applicable

Completed

Conditions: Malaria,Falciparum
Malaria

Interventions: Drug: Dihydroartemisinin-piperaquine
Drug: Primaquine

First Posted Date: 2021-04-28

Last Posted Date: 2024-06-24

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10715

Registration Number: NCT04864444

Locations: 🇸🇳
Tambacounda Health District, Tambacounda, Senegal

Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure

Phase 4

Completed

Conditions: Vivax Malaria

Interventions: Drug: Primaquine
Drug: Artesunate

First Posted Date: 2021-01-12

Last Posted Date: 2025-03-28

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 160

Registration Number: NCT04706130

Locations: 🇰🇭
Institut Pasteur du Cambodge, Phnom Penh, Cambodia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy